A panel of experts discusses the rising class of biological agents and why clinical pharmacists need to deepen their knowledge.
Clinical pharmacists can play an important role in educating consumers about biosimilars, but they need to familiarize themselves with these products, said an expert panel recently.
“Clinical pharmacists are in a unique position to provide appropriate patient and provider education. There’s also an increased impact by pharmacists in managing the formularies with multiple biosimilars available,” Antony Mato, MD, MSCE, said.
To do this, they need to know the difference between different biologics, which represent the fastest growing therapeutic class of drugs. In 2017, an estimated $120.1 billion was spent on biological medicines, up from $76.9 billion in 2013, according to a Forbes analysis.
The panel said clinical pharmacists may be more familiar with small molecule drugs.
Indeed, a recent study by the International Society of Oncology Pharmacy Practitioners revealed that pharmacists feel they lack knowledge when it comes to comparing the efficacy of biosimilars with originator products (74.4%), switching patients to biosimilars from originator products (74.4%), and understanding the safety of biosimilars (73.3%).
Limited financial support, heavy workloads, and poor educational resources were identified as challenges to expanding their knowledge of biosimilars.
“For small-molecule drugs, the brand originator versus the generic, it’s very easy to re-create these identical copies with a chemical synthesis. We have these raw materials that we know the chemical formula for, so we can make these copies,” Tim Peterson, PharmD, BCOP, said, in the panel discussion.
Biologics are developed from recombinant DNA using a vector inserted into a host cell. They can be very large molecules with high molecular weights. This means that there are differences in amino acid sequences, protein aggregation and folding, and variability between manufacturers in processing.
For the full story on the panel discussion, visit Pharmacy Times.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.